Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

NCT02992522 is registered in ClinicalTrials.gov with Beth Christian as lead sponsor.

NCT NCT02992522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02992522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Lead sponsor
Beth Christian
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 21, 2017
Completion date
April 15, 2027
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell, b-cell lymphoma, unspecified, grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma, recurrent burkitt lymphoma, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent marginal zone lymphoma, refractory burkitt lymphoma, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, transformed recurrent non-hodgkin lymphoma